Article: article from journal or magazin.
Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
Journal of Clinical Oncology
Publication types: Journal Article ; Multicenter Study
PURPOSE: We conducted a retrospective analysis to evaluate the safety and efficacy of Campath-1H, an anti-CD52 humanized monoclonal antibody, in previously treated T-prolymphocytic leukemia (T-PLL) patients in a compassionate-use program. PATIENTS AND METHODS: Seventy-six patients with T-PLL (including four chemotherapy-naive patients) received 3, 10, and 30 mg of Campath-1H on sequential days, followed by 30 mg three times weekly, as 2-hour intravenous infusions, for 4 to 12 weeks. RESULTS: Median patient age was 60 years (range, 35 to 84). Spleen liver, lymph node, and skin involvement were present in 64%, 40%, 54%, and 18% of patients, respectively. All tested patients had CD2, CD7, CD4, and/or CD8 positivity, whereas CD5 and CD3 were positive in 98% and 96% of tested patients, respectively. The objective response rate was 51% (95% confidence interval [CI], 40% to 63%), with a 39.5% complete response (CR) rate (95% CI, 28% to 51%). The median duration of CR was 8.7 months (range, 0.13+ to 44.4), and median time to progression was 4.5 months (range, 0.1 to 45.4) compared with 2.3 months (range, 0.2 to 28.1) after first-line chemotherapy. The median overall survival was 7.5 months (14.8 months for CR patients). The most common Campath-1H-related adverse events were acute reactions during or immediately after infusions. Fifteen infectious episodes occurred during treatment in 10 patients (13%), leading to treatment discontinuation in three. Eight patients experienced possibly related, late-onset infections. Severe thrombocytopenia and/or neutropenia occurred in six patients (8%), leading to treatment discontinuation in four. Two treatment-related deaths occurred. CONCLUSION: Campath-1H is an active drug in T-PLL patients for whom first-line therapy has failed. It has a favorable risk/benefit ratio and should be prospectively investigated in chemotherapy-naive patients.
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal/adverse effects, Antibodies, Monoclonal/therapeutic use, Antibodies, Neoplasm/adverse effects, Antibodies, Neoplasm/therapeutic use, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Consumer Product Safety, Female, Hematologic Diseases/chemically induced, Hematologic Diseases/epidemiology, Humans, Infusions, Intravenous, Leukemia, T-Cell/drug therapy, Leukemia, T-Cell/mortality, Male, Middle Aged, Opportunistic Infections/chemically induced, Opportunistic Infections/epidemiology, Retrospective Studies, Salvage Therapy/methods, Survival Rate, Time Factors
Web of science
Last modification date